David Hirsch
Managing Director @ Longitude Capital
Boston, United States
David Hirsch is a Series B investor at Longitude Capital in Boston focused on Biotechnology and Medical. David J. Hirsch is based out of Boston, Massachusetts and currently works as a Consultant for Barron Mountain Consultants. David previously worked at Alpha-9 Oncology as a Chief Executive Officer. David J. Hirsch attended the Massachusetts Institute of Technology.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries David Hirsch invests in
Stages David Hirsch invests in
Countries David Hirsch invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 7 (54%)
- Medical 4 (31%)
- Therapeutics 4 (31%)
- Pharmaceutical 2 (15%)
- Genetics 1 (8%)
Stage
- Series B 4 (31%)
- Series A 3 (23%)
- Series C 3 (23%)
- Private Equity 2 (15%)
- Venture - Series Unknown 1 (8%)
Country
- United States 5 (38%)
- Canada 1 (8%)
- Ireland 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Alpha9 Theranostics is a clinical-stage biopharmaceutical company. | $175M / Series C / Oct 23, 2024 | ||
| Alpha9 Theranostics is a clinical-stage biopharmaceutical company. | $8.9M / Series A / Apr 28, 2021 | ||
| Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness theimmune system, it aims to conquer cancer and save lives. Its pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform and have ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical technologies.Amunix was founded in 2006 and is headquartered in Mountain View, California. | $117M / Series B / Mar 04, 2021 | ||
| Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $120M / Private Equity / May 20, 2020 | ||
| Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness theimmune system, it aims to conquer cancer and save lives. Its pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform and have ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical technologies.Amunix was founded in 2006 and is headquartered in Mountain View, California. | $73M / Series A / Mar 04, 2020 | ||
| Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our coreproprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. | $142M / Series C / Apr 22, 2019 | ||
| Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes. The company's drugs block inflammasome signals, eliminating a root cause of inflammation, enabling healthcare institutions to avail targeted therapies for inflammatory diseases such as Parkinson's,Alzheimer's, atherosclerosis, and type 2 diabetes.The company was incorporated in 2016 and is headquartered in Dublin, Ireland. | $45.8M / Series B / Nov 19, 2018 | ||
| Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our coreproprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. | $30.5M / Series B / Apr 03, 2018 | ||
| Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. | $45M / Series A / Mar 30, 2016 | ||
| Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $25M / Series C / Apr 29, 2015 | ||
| See all 13 investments → | |||
Co-Investors
About Longitude Capital
Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance the quality of life, and/or reduce system costs. They invest in both privately held and publicly traded life science companies through a variety of investment approaches. Since 2006, Longitude Capital has raised over $1.2 billion across three funds and demonstrated an ability to source, manage and exit attractive investments across multiple market cycles. Their venture growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile, and attractive expected returns within three to five years from the initial investment. Longitude Capital seeks to identify new investment opportunities by tapping into their broad network of industry relationships or through the execution of intensive thematic research into emerging therapeutic areas or industry sub-sectors. They utilize a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity and equity-linked instruments.
Longitude Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amar Patel
Associate
|
|||
Brian Liu
Principal; Vice President
|
|||
|
David Hirsch
Managing Director
|
|||
Juliet Tammenoms Bakker
Co-Founder and Managing Director
|
|||
Karthik Bolisetty
Associate
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does David Hirsch invest in?
David Hirsch invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series B and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact David Hirsch?
Public channels for David Hirsch include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did David Hirsch last invest?
The most recent investment recorded for David Hirsch closed in Oct 2024. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
